BACKGROUND AND PURPOSE: Injury to the lung parenchyma is a constitutional feature shared by many lung diseases. The protein, phosphatase and tensin homologue deleted on chromosome Ten (PTEN) is a major suppressor of phosphoinositide-3 kinase/Akt signalling, a vital survival pathway in lung parenchymal cells. Based on this, we hypothesized that PTEN inhibition in vivo would enhance cell tolerance to stress thereby preventing acute lung injury. EXPERIMENTAL APPROACH: We evaluated the ability of a PTEN inhibitor, potassium bisperoxo (1,10-phenanthroline) oxovanadate [bpV(phen)], to prevent acute lung injury induced by oleic acid (OA) in adult C57BL/6 mice. Lung assessments included bronchoalveolar lavage, tissue morphology, immunostaining for markers of cell death, cell identity, phospho-Akt and phospho-ERK levels and oximetry. KEY RESULTS: OA induced acute lung injury in a dose- and time-dependent manner. No injury was observed in the vehicle control or bpV(phen) treatment groups. PTEN inhibition by bpV(phen) increased lung tissue levels of phospho-Akt and ERK and but not focal adhesion kinase. This occurred in conjunction with a statistically significant reduction in protein content, lactate dehydrogenase, as well as tumour necrosis factor-alpha and chemokines in bronchoalveolar lavage fluid when compared with OA treatment alone. The incidence of alveolar lesions, consistent with acute lung injury, and terminal uridine deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-positive cells was also significantly reduced. Importantly, PTEN suppression maintained pulmonary function. CONCLUSIONS AND IMPLICATIONS: Treatment with bpV(phen) significantly reduced the severity of acute lung injury in mice indicating that additional investigation is warranted to understand the important role that this phosphatase may play in the lung.
BACKGROUND AND PURPOSE:Injury to the lung parenchyma is a constitutional feature shared by many lung diseases. The protein, phosphatase and tensin homologue deleted on chromosome Ten (PTEN) is a major suppressor of phosphoinositide-3 kinase/Akt signalling, a vital survival pathway in lung parenchymal cells. Based on this, we hypothesized that PTEN inhibition in vivo would enhance cell tolerance to stress thereby preventing acute lung injury. EXPERIMENTAL APPROACH: We evaluated the ability of a PTEN inhibitor, potassium bisperoxo (1,10-phenanthroline) oxovanadate [bpV(phen)], to prevent acute lung injury induced by oleic acid (OA) in adult C57BL/6 mice. Lung assessments included bronchoalveolar lavage, tissue morphology, immunostaining for markers of cell death, cell identity, phospho-Akt and phospho-ERK levels and oximetry. KEY RESULTS:OA induced acute lung injury in a dose- and time-dependent manner. No injury was observed in the vehicle control or bpV(phen) treatment groups. PTEN inhibition by bpV(phen) increased lung tissue levels of phospho-Akt and ERK and but not focal adhesion kinase. This occurred in conjunction with a statistically significant reduction in protein content, lactate dehydrogenase, as well as tumour necrosis factor-alpha and chemokines in bronchoalveolar lavage fluid when compared with OA treatment alone. The incidence of alveolar lesions, consistent with acute lung injury, and terminal uridine deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-positive cells was also significantly reduced. Importantly, PTEN suppression maintained pulmonary function. CONCLUSIONS AND IMPLICATIONS: Treatment with bpV(phen) significantly reduced the severity of acute lung injury in mice indicating that additional investigation is warranted to understand the important role that this phosphatase may play in the lung.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: L L Mantell; J A Kazzaz; J Xu; T A Palaia; B Piedboeuf; S Hall; G C Rhodes; G Niu; A F Fein; S Horowitz Journal: Cell Death Differ Date: 1997-10 Impact factor: 15.828
Authors: M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks Journal: Proc Natl Acad Sci U S A Date: 1998-11-10 Impact factor: 11.205
Authors: Eric S White; Victor J Thannickal; Shannon L Carskadon; Emily G Dickie; Donna L Livant; Sonja Markwart; Galen B Toews; Douglas A Arenberg Journal: Am J Respir Crit Care Med Date: 2003-06-05 Impact factor: 21.405
Authors: Sarah Navina; Chathur Acharya; James P DeLany; Lidiya S Orlichenko; Catherine J Baty; Sruti S Shiva; Chandra Durgampudi; Jenny M Karlsson; Kenneth Lee; Kyongtae T Bae; Alessandro Furlan; Jaideep Behari; Shiguang Liu; Teresa McHale; Larry Nichols; Georgios Ioannis Papachristou; Dhiraj Yadav; Vijay P Singh Journal: Sci Transl Med Date: 2011-11-02 Impact factor: 17.956
Authors: George D Leikauf; Hannah Pope-Varsalona; Vincent J Concel; Pengyuan Liu; Kiflai Bein; Annerose Berndt; Timothy M Martin; Koustav Ganguly; An Soo Jang; Kelly A Brant; Richard A Dopico; Swapna Upadhyay; Y P Peter Di; Qian Li; Zhen Hu; Louis J Vuga; Mario Medvedovic; Naftali Kaminski; Ming You; Danny C Alexander; Jonathan E McDunn; Daniel R Prows; Daren L Knoell; James P Fabisiak Journal: Am J Respir Cell Mol Biol Date: 2012-03-23 Impact factor: 6.914
Authors: Jarrod E Church; Jin Qian; Sanjiv Kumar; Stephen M Black; Richard C Venema; Andreas Papapetropoulos; David J R Fulton Journal: Vascul Pharmacol Date: 2009-12-03 Impact factor: 5.773